Denali Therapeutics Inc., A Biopharmaceutical Company, And Biogen Inc. Announced That Dosing Has Commenced In The Global Phase 2B Luma Study To Evaluate The Efficacy And Safety Of Biib122 (Dnl151), As Compared To Placebo In Approximately 640 Participants With Early-Stage Parkinson
